Concepts (158)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension | 10 | 2024 | 498 | 4.290 |
Why?
|
| Antihypertensive Agents | 8 | 2024 | 159 | 3.110 |
Why?
|
| Atherosclerosis | 4 | 2025 | 53 | 2.420 |
Why?
|
| Cardiovascular Diseases | 6 | 2023 | 596 | 2.060 |
Why?
|
| Atrial Fibrillation | 5 | 2023 | 171 | 1.910 |
Why?
|
| Arthritis, Rheumatoid | 3 | 2019 | 22 | 1.670 |
Why?
|
| Diabetes Complications | 3 | 2021 | 113 | 1.670 |
Why?
|
| Medication Adherence | 6 | 2020 | 245 | 1.640 |
Why?
|
| Stroke | 6 | 2023 | 316 | 1.440 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2023 | 181 | 1.420 |
Why?
|
| Humans | 36 | 2025 | 17707 | 1.340 |
Why?
|
| Aged | 22 | 2025 | 6150 | 1.320 |
Why?
|
| Diabetes Mellitus | 4 | 2018 | 483 | 1.310 |
Why?
|
| Retrospective Studies | 17 | 2024 | 2471 | 1.280 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 5 | 2023 | 86 | 1.260 |
Why?
|
| Delivery of Health Care, Integrated | 5 | 2023 | 531 | 1.230 |
Why?
|
| Warfarin | 3 | 2021 | 74 | 1.170 |
Why?
|
| Middle Aged | 23 | 2025 | 7976 | 1.150 |
Why?
|
| Blood Pressure | 4 | 2024 | 300 | 1.130 |
Why?
|
| Adult | 19 | 2025 | 7658 | 1.100 |
Why?
|
| Male | 24 | 2025 | 10094 | 1.020 |
Why?
|
| Hypoglycemic Agents | 4 | 2016 | 271 | 0.990 |
Why?
|
| Female | 23 | 2025 | 12729 | 0.960 |
Why?
|
| Aspirin | 2 | 2015 | 63 | 0.950 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2024 | 755 | 0.900 |
Why?
|
| Anticoagulants | 3 | 2023 | 128 | 0.880 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2021 | 53 | 0.850 |
Why?
|
| Embolism | 1 | 2023 | 6 | 0.850 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2023 | 7 | 0.840 |
Why?
|
| Hyperkalemia | 1 | 2023 | 16 | 0.830 |
Why?
|
| Comorbidity | 8 | 2020 | 590 | 0.790 |
Why?
|
| Risk Factors | 10 | 2025 | 3367 | 0.760 |
Why?
|
| Diabetic Nephropathies | 1 | 2021 | 26 | 0.750 |
Why?
|
| Aged, 80 and over | 10 | 2020 | 1927 | 0.750 |
Why?
|
| Prevalence | 7 | 2022 | 882 | 0.740 |
Why?
|
| Health Expenditures | 2 | 2019 | 70 | 0.710 |
Why?
|
| Calcium Channel Blockers | 1 | 2020 | 14 | 0.710 |
Why?
|
| Treatment Outcome | 6 | 2024 | 1254 | 0.700 |
Why?
|
| Health Care Costs | 2 | 2020 | 222 | 0.700 |
Why?
|
| Diabetic Retinopathy | 2 | 2018 | 19 | 0.690 |
Why?
|
| Hemorrhage | 2 | 2023 | 62 | 0.690 |
Why?
|
| Young Adult | 8 | 2023 | 2450 | 0.680 |
Why?
|
| Cholesterol, LDL | 2 | 2016 | 119 | 0.630 |
Why?
|
| Antiviral Agents | 1 | 2019 | 94 | 0.620 |
Why?
|
| Hepatitis C | 1 | 2019 | 64 | 0.620 |
Why?
|
| California | 7 | 2025 | 2327 | 0.590 |
Why?
|
| Risk Assessment | 6 | 2025 | 1106 | 0.580 |
Why?
|
| Cost of Illness | 1 | 2018 | 94 | 0.580 |
Why?
|
| United States | 6 | 2025 | 3914 | 0.570 |
Why?
|
| Societies, Medical | 1 | 2018 | 74 | 0.570 |
Why?
|
| Guideline Adherence | 1 | 2018 | 155 | 0.530 |
Why?
|
| Hyperlipidemias | 1 | 2016 | 53 | 0.520 |
Why?
|
| Adolescent | 7 | 2021 | 3671 | 0.500 |
Why?
|
| Incidence | 4 | 2023 | 1269 | 0.500 |
Why?
|
| Blood Coagulation | 1 | 2015 | 2 | 0.500 |
Why?
|
| Quality of Life | 1 | 2019 | 521 | 0.490 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2015 | 24 | 0.490 |
Why?
|
| Fibrinolytic Agents | 1 | 2015 | 44 | 0.480 |
Why?
|
| Drug Therapy, Combination | 3 | 2021 | 115 | 0.470 |
Why?
|
| Natural Language Processing | 1 | 2015 | 58 | 0.460 |
Why?
|
| Patient-Centered Care | 1 | 2016 | 194 | 0.460 |
Why?
|
| Mass Screening | 2 | 2018 | 667 | 0.450 |
Why?
|
| Quality of Health Care | 1 | 2016 | 276 | 0.450 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2016 | 172 | 0.450 |
Why?
|
| Managed Care Programs | 1 | 2016 | 313 | 0.450 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2016 | 387 | 0.420 |
Why?
|
| Time Factors | 3 | 2025 | 1095 | 0.400 |
Why?
|
| Administration, Oral | 3 | 2023 | 84 | 0.390 |
Why?
|
| Electronic Health Records | 1 | 2015 | 694 | 0.340 |
Why?
|
| Surveys and Questionnaires | 3 | 2019 | 1322 | 0.330 |
Why?
|
| Myocardial Infarction | 3 | 2021 | 234 | 0.320 |
Why?
|
| International Normalized Ratio | 2 | 2017 | 22 | 0.260 |
Why?
|
| Osteoarthritis | 2 | 2016 | 15 | 0.260 |
Why?
|
| Multivariate Analysis | 2 | 2019 | 561 | 0.240 |
Why?
|
| Case-Control Studies | 2 | 2019 | 1117 | 0.230 |
Why?
|
| Proteinuria | 1 | 2024 | 26 | 0.230 |
Why?
|
| Logistic Models | 2 | 2019 | 918 | 0.230 |
Why?
|
| Predictive Value of Tests | 1 | 2025 | 355 | 0.220 |
Why?
|
| Rivaroxaban | 1 | 2023 | 8 | 0.210 |
Why?
|
| Pyridones | 1 | 2023 | 8 | 0.210 |
Why?
|
| Dabigatran | 1 | 2023 | 8 | 0.210 |
Why?
|
| Longitudinal Studies | 2 | 2016 | 717 | 0.210 |
Why?
|
| Aldosterone | 1 | 2023 | 2 | 0.210 |
Why?
|
| Potassium | 1 | 2023 | 16 | 0.210 |
Why?
|
| Creatinine | 1 | 2023 | 65 | 0.210 |
Why?
|
| Renin-Angiotensin System | 1 | 2023 | 17 | 0.210 |
Why?
|
| Diuretics | 1 | 2022 | 17 | 0.200 |
Why?
|
| Age Factors | 3 | 2020 | 918 | 0.200 |
Why?
|
| Cost-Benefit Analysis | 1 | 2023 | 243 | 0.200 |
Why?
|
| Spironolactone | 1 | 2021 | 6 | 0.190 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2021 | 10 | 0.190 |
Why?
|
| Angioedema | 1 | 2021 | 6 | 0.190 |
Why?
|
| Kidney Diseases | 1 | 2021 | 53 | 0.190 |
Why?
|
| Bioprosthesis | 1 | 2021 | 2 | 0.180 |
Why?
|
| Heart Valves | 1 | 2021 | 4 | 0.180 |
Why?
|
| Heart Valve Diseases | 1 | 2021 | 20 | 0.180 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2020 | 9 | 0.180 |
Why?
|
| Drug Combinations | 1 | 2020 | 43 | 0.180 |
Why?
|
| Coinfection | 1 | 2020 | 30 | 0.170 |
Why?
|
| Recurrence | 1 | 2020 | 189 | 0.170 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2020 | 29 | 0.170 |
Why?
|
| Physicians | 1 | 2021 | 135 | 0.170 |
Why?
|
| Social Class | 1 | 2020 | 121 | 0.170 |
Why?
|
| Reproducibility of Results | 2 | 2021 | 371 | 0.160 |
Why?
|
| Drug Monitoring | 2 | 2017 | 21 | 0.160 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 397 | 0.160 |
Why?
|
| Sex Factors | 1 | 2020 | 639 | 0.150 |
Why?
|
| Brain Ischemia | 2 | 2008 | 37 | 0.150 |
Why?
|
| European Continental Ancestry Group | 1 | 2020 | 523 | 0.150 |
Why?
|
| Ethnic Groups | 1 | 2020 | 474 | 0.140 |
Why?
|
| Canada | 1 | 2017 | 66 | 0.140 |
Why?
|
| Influenza, Human | 1 | 2020 | 267 | 0.140 |
Why?
|
| Testosterone | 1 | 2017 | 23 | 0.140 |
Why?
|
| Sensitivity and Specificity | 2 | 2015 | 304 | 0.140 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2017 | 35 | 0.140 |
Why?
|
| Hospitalization | 2 | 2020 | 805 | 0.130 |
Why?
|
| Chronic Disease | 1 | 2019 | 416 | 0.130 |
Why?
|
| Heart Failure | 1 | 2021 | 398 | 0.130 |
Why?
|
| Cohort Studies | 2 | 2020 | 2589 | 0.130 |
Why?
|
| Information Storage and Retrieval | 1 | 2015 | 14 | 0.120 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 710 | 0.120 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 1218 | 0.110 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 1322 | 0.110 |
Why?
|
| Algorithms | 1 | 2015 | 237 | 0.110 |
Why?
|
| Renal Insufficiency | 1 | 2013 | 13 | 0.110 |
Why?
|
| Causality | 1 | 2013 | 39 | 0.110 |
Why?
|
| Health Maintenance Organizations | 1 | 2015 | 414 | 0.110 |
Why?
|
| Budgets | 1 | 2011 | 5 | 0.090 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2010 | 25 | 0.090 |
Why?
|
| Cost Sharing | 1 | 2010 | 30 | 0.090 |
Why?
|
| Leukoaraiosis | 1 | 2008 | 1 | 0.080 |
Why?
|
| Prostatic Neoplasms | 1 | 2011 | 262 | 0.080 |
Why?
|
| Early Detection of Cancer | 1 | 2011 | 513 | 0.060 |
Why?
|
| Quality Improvement | 1 | 2023 | 189 | 0.050 |
Why?
|
| Orthomyxoviridae | 1 | 2020 | 5 | 0.040 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2020 | 21 | 0.040 |
Why?
|
| Geriatric Assessment | 1 | 2020 | 41 | 0.040 |
Why?
|
| Seasons | 1 | 2020 | 105 | 0.040 |
Why?
|
| Pandemics | 1 | 2021 | 286 | 0.040 |
Why?
|
| Androgens | 1 | 2017 | 13 | 0.030 |
Why?
|
| Drug Administration Routes | 1 | 2017 | 5 | 0.030 |
Why?
|
| Hormone Replacement Therapy | 1 | 2017 | 22 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2017 | 62 | 0.030 |
Why?
|
| Models, Economic | 1 | 2011 | 17 | 0.020 |
Why?
|
| Reference Values | 1 | 2011 | 93 | 0.020 |
Why?
|
| Probability | 1 | 2011 | 78 | 0.020 |
Why?
|
| Prostate-Specific Antigen | 1 | 2011 | 75 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2011 | 81 | 0.020 |
Why?
|
| Insurance Claim Review | 1 | 2010 | 57 | 0.020 |
Why?
|
| Propensity Score | 1 | 2010 | 85 | 0.020 |
Why?
|
| Constriction, Pathologic | 1 | 2008 | 2 | 0.020 |
Why?
|
| Korea | 1 | 2008 | 9 | 0.020 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2008 | 8 | 0.020 |
Why?
|
| Arteries | 1 | 2008 | 8 | 0.020 |
Why?
|
| Cerebral Angiography | 1 | 2008 | 6 | 0.020 |
Why?
|
| Asian Continental Ancestry Group | 1 | 2008 | 90 | 0.020 |
Why?
|
| Brain | 1 | 2008 | 47 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2008 | 296 | 0.020 |
Why?
|
Concepts
(158)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(13)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
-->